The market has climbed 4.9% in the last 7 days and is up 21% over the past year, with earnings forecasted to grow by 17% annually. Investing in penny stocks—once a buzzword but now more of a niche—can still open doors to growth opportunities, especially when these stocks are supported by strong financial health. For those looking to invest in smaller or newer companies, penny stocks can offer surprising value and potential for long-term growth.

Below we spotlight a couple of our favorites from our exclusive screener.

ProKidney (PROK)

Simply Wall St Financial Health Rating: ★★★★★★

Overview: ProKidney Corp. is a clinical-stage biotechnology company focused on developing cell therapies for chronic kidney diseases in the United States, with a market cap of approximately $490.85 million.

Operations: ProKidney's revenue segment is derived entirely from its biotechnology startups, amounting to $0.89 million.

Market Cap: $490.85M

ProKidney, a clinical-stage biotech firm with a market cap of US$490.85 million, is pre-revenue with sales of US$0.89 million and remains unprofitable. Despite this, its short-term assets significantly exceed both short- and long-term liabilities, providing financial stability. The company has been added to multiple Russell indexes recently, which may increase investor visibility. ProKidney's management team is experienced, and it has no debt on its balance sheet. However, the company faces challenges in achieving profitability soon as losses have increased over the past five years by 13.7% annually while revenue growth remains limited.

Smart Sand (SND)

Simply Wall St Financial Health Rating: ★★★★★☆

Overview: Smart Sand, Inc. is a fully integrated company that supplies and services frac and industrial sand, offering mine to wellsite proppant supply and logistics solutions in the United States and Canada, with a market cap of $185.70 million.

Operations: The company's revenue is primarily derived from its Sand segment, which generated $353.79 million, complemented by $3.92 million from its Smartsystems segment.

Market Cap: $185.7M

Smart Sand, Inc., with a market cap of US$185.70 million, has shown improved financial health as its debt to equity ratio decreased from 9.6% to 5.8% over five years and its debt is well covered by operating cash flow at 281.5%. The company became profitable recently, although insider selling was significant in the past three months and return on equity remains low at 9.3%. Smart Sand's addition to multiple Russell indexes may enhance visibility among investors, while the board and management team bring extensive experience with average tenures of over a decade each.

Valens Semiconductor (VLN)

Simply Wall St Financial Health Rating: ★★★★★★

Overview: Valens Semiconductor Ltd. develops semiconductor products for the audio-video and automotive industries, with a market cap of $176.48 million.

Operations: The company generates revenue from two main segments: Automotive, contributing $19.77 million, and Cross Industry Business (CIB), which accounts for $50.89 million.

Market Cap: $176.48M

Valens Semiconductor, with a market cap of US$176.48 million, is navigating the penny stock landscape with strategic leadership changes and solid financial footing. The company boasts a cash runway exceeding three years without debt, supported by short-term assets of US$113 million that surpass both short- and long-term liabilities. Despite being unprofitable, Valens has reduced losses over five years and anticipates revenue growth of 18.84% annually. Recent executive appointments aim to bolster its automotive segment, while partnerships like the integration of HDBaseT chipsets in Barco NV's products highlight its role in high-performance connectivity solutions.

Seize The Opportunity

• Unlock more gems! Our US Penny Stocks screener has unearthed 329 more companies for you to explore.Click here to unveil our expertly curated list of 332 US Penny Stocks.
• Looking For Alternative Opportunities? The end of cancer? These 33 emerging AI stocks are developing tech that will allow early idenification of life changing disesaes like cancer and Alzheimer's.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.